JPS62158490A - Treatment of panax ginseng - Google Patents

Treatment of panax ginseng

Info

Publication number
JPS62158490A
JPS62158490A JP169586A JP169586A JPS62158490A JP S62158490 A JPS62158490 A JP S62158490A JP 169586 A JP169586 A JP 169586A JP 169586 A JP169586 A JP 169586A JP S62158490 A JPS62158490 A JP S62158490A
Authority
JP
Japan
Prior art keywords
ginsenoside
ginseng
treatment
high temperature
tissue culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP169586A
Other languages
Japanese (ja)
Inventor
Yoshie Ishida
石田 義枝
Toshiji Oba
利治 大場
Yoshinori Miyamoto
宮本 芳則
Toshiyuki Kikuchi
菊地 敏行
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Electric Industrial Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Electric Industrial Co Ltd filed Critical Nitto Electric Industrial Co Ltd
Priority to JP169586A priority Critical patent/JPS62158490A/en
Publication of JPS62158490A publication Critical patent/JPS62158490A/en
Pending legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PURPOSE:To obtain Panax ginseng having high ginsenoside Rh content and preservable over a long period, at a low cost, by treating a tissue culture product of Panax ginseng at a high temperature and drying under specific condition. CONSTITUTION:A tissue culture product of Panax ginseng is heat-treated in a closed vessel at 110-160 deg.C for 0.5-24hr. The ginsenoside Rh content of the tissue is increased by this process. The heat-treated product is dried at a temperature lower than the above heat-treatment temperature, i.e. with hot air of 40-60 deg.C to enable the long-term preservation of the tissue.

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は制癌効果を有するとされるジンセノサイドRh
の含有量を高める薬用人参の処理方法、特に薬用人参の
組織培養物の処理方法に関する。
DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention is directed to the use of ginsenoside Rh, which is said to have an anticancer effect.
The present invention relates to a method for processing medicinal ginseng to increase the content of medicinal ginseng, particularly a method for processing a tissue culture of medicinal ginseng.

(従来の技術) 薬用人参2例えば、オタネ人参(Panax gins
engC1八、 Meyer)、チクセツ人参(r’a
nax japonicusC,A、 Meyer)、
  アメリカ人参(Panax quinquefol
iumL、)、三七人参(Panax noLo(Hi
nseng  (Burk) F。
(Prior art) Medicinal ginseng 2 For example, Panax gins
engC18, Meyer), Chikusetsu ginseng (r'a
nax japonicus C, A, Meyer),
American ginseng (Panax quinquefol)
), Panax noLo(Hi
nseng (Burk) F.

If、 Chen)、  シベリア人参(Eleu t
herococcussenticosus)の根、は
有用漢方薬として珍重され広く利用されている。薬効と
しては、古くから強壮、長生などが言われ、現在では鎮
静、興奮、利尿作用なども明らかにされている。薬用人
参の有効成分は主としてサポニンである。薬用人参のサ
ポニンはジンセノサイドと総称され、現在までにジンセ
ノサイドRo、  ジンセノサイドRa、  ジンセノ
サイドRb、  ジンセノサイドRc、  ジンセノサ
イドRd。
If, Chen), Siberian ginseng (Eleut)
herococcus senticosus) root is prized and widely used as a useful herbal medicine. Its medicinal properties have long been said to include tonicity and longevity, and its sedative, stimulant, and diuretic effects have now been revealed. The active ingredients of medicinal ginseng are mainly saponins. The saponins of medicinal ginseng are collectively called ginsenosides, and to date they have been classified as ginsenoside Ro, ginsenoside Ra, ginsenoside Rb, ginsenoside Rc, and ginsenoside Rd.

ジンセノサイドRe、  ジンセノサイドRf、  ジ
ンセノサイドR,gおよびジンセノサイドRhが知られ
ている。
Ginsenoside Re, ginsenoside Rf, ginsenoside R,g and ginsenoside Rh are known.

これらのうらジンセノサイドRhが鎮静作用を、ジンセ
ノサイドRgが興奮作用を示すことが報告されている(
薬学雑誌82巻12号1633〜1634頁;蛋白質。
It has been reported that ginsenoside Rh has a sedative effect and ginsenoside Rg has a stimulatory effect (
Pharmaceutical Journal Vol. 82, No. 12, pp. 1633-1634; Protein.

核酸、酵素12巻1号32〜38頁)。ジンセノサイド
11c、 RdおよびReについても、血清コレステロ
ールの合成促進などの生理活性が報告されている。
Nucleic Acids, Enzymes, Vol. 12, No. 1, pp. 32-38). Ginsenosides 11c, Rd, and Re have also been reported to have physiological activities such as promotion of serum cholesterol synthesis.

ジンセノサイドRhは制癌作用を有すると言われるが、
天然の薬用人参のジンセノサイドRh含量は極めて低く
、なかには検出されない場合もあるため。
Ginsenoside Rh is said to have anticancer effects, but
The ginsenoside Rh content of natural medicinal ginseng is extremely low and may not be detected in some cases.

その研究が遅れている。ジンセノサイドRhを多量に含
有する人参が得られれば、ジンセノサイドRhについて
の研究も進み、その薬効も明らかにされると考えられる
That research is lagging behind. If ginseng containing a large amount of ginsenoside Rh can be obtained, research on ginsenoside Rh will progress and its medicinal efficacy will be clarified.

(発明が解決しようとする問題点) 本発明は、上記従来の欠点を解決するものであり、その
目的とするところは薬用人参中のジンセノサイドRhの
含有量を高める方法を提供することにある。本発明の他
の目的は、天然の薬用人参に比べて調製の容易な薬用人
参組織培養物を利用し。
(Problems to be Solved by the Invention) The present invention solves the above-mentioned conventional drawbacks, and its purpose is to provide a method for increasing the content of ginsenoside Rh in medicinal ginseng. Another object of the present invention is to utilize a ginseng tissue culture that is easier to prepare than natural ginseng.

これに含有されるジンセノサイドRhの量を高めるため
の処理方法を提供することにある。
It is an object of the present invention to provide a treatment method for increasing the amount of ginsenoside Rh contained in this.

(問題点を解決するための手段および作用)本発明の薬
用人参の処理方法は、薬用人参から得られる組織培養物
を高温処理しジンセノサイドRhの含有量を高める工程
を包含し、そのことにより上記目的が達成される。
(Means and effects for solving the problems) The method for treating medicinal ginseng of the present invention includes the step of treating a tissue culture obtained from medicinal ginseng at high temperature to increase the content of ginsenoside Rh, thereby increasing the content of ginsenoside Rh. The purpose is achieved.

本発明で用いられる薬用人参の組織培養物は。The medicinal ginseng tissue culture used in the present invention is:

通常の植物組織培養法により得られる。例えば。Obtained by conventional plant tissue culture methods. for example.

オタネ人参、チクセツ人参、アメリカ人参、三七人参、
シベリア人参などの既知の薬用人参の組織を培養してカ
ルスを発生させる。次に、得られたカルスを液体培養法
や固体培養法により増殖させる。このカル、スは培養に
より無限に増殖させられうる。培養条件は何ら格別であ
る必要はない。培地としては、植物培養に通常用いられ
るムラシゲ−スクーグ(Murashige−5koo
g)の培地、ホワイト(Wh i te)の培地、オー
、エル、ガンボーグ(0,L。
Panax ginseng, Panax ginseng, American ginseng, Panax ginseng,
Tissues of known medicinal ginseng, such as Siberian ginseng, are cultured to generate callus. Next, the obtained callus is grown by a liquid culture method or a solid culture method. This callus can be grown indefinitely by culturing. Culture conditions do not need to be particularly special. The medium used is Murashige-5koog, which is commonly used for plant culture.
g) medium, White's medium, O, L, Gamborg (0,L).

Gamborg)のB5培地、ニッチュ(Nitsch
)の培地。
Gamborg's B5 medium, Nitsch
) medium.

ヘラ−(lleller)の培地、モーレル(More
l)の培地などを用いることが可能である。これに、必
要であれば、カゼイン分解酵素、大豆粉、コーンステイ
ープリカー、ビタミン類などが添加されうる。
Heller's medium, Morel
It is possible to use a medium such as 1). If necessary, casein degrading enzyme, soybean flour, cornstarch liquor, vitamins, etc. can be added to this.

培養法の詳細は1例えば、特開昭59−169486号
公報、特開昭59−169487号公報、特開昭59−
16488号公報に開示されている。液体培養法を採用
すれば。
Details of the culture method can be found in 1, for example, JP-A-59-169486, JP-A-59-169487, JP-A-59-
It is disclosed in Japanese Patent No. 16488. If liquid culture method is adopted.

得られる組織培養物の細胞塊は、振とうもしくは攪拌に
より、極端に大きくなることはなく最大直径はせいぜい
15mm程度である。このような細胞塊は粒径が揃って
いるため、後述の高温処理の後ジンセノサイドを抽出す
るのに便利である。得られた細胞培養物は、必要に応じ
て、濾過、遠心分離などにより過剰の水分を除いて9次
の高温処理に供される。
The resulting tissue culture cell mass does not become extremely large when shaken or stirred, and its maximum diameter is approximately 15 mm at most. Since such cell clusters have uniform particle sizes, they are convenient for extracting ginsenosides after high-temperature treatment as described below. The obtained cell culture is subjected to a ninth high-temperature treatment after removing excess water by filtration, centrifugation, etc., if necessary.

高温処理は、上記組織培養物を1通常、110〜160
℃1好ましくは120〜150℃に加熱して行われる。
The high temperature treatment is carried out by heating the above tissue culture at a temperature of 110 to 160%.
C.1, preferably 120 to 150.degree.

処理時間は通常、0.5〜24時間、好ましくは1〜1
0時間である。例えば、110℃では高温処理時間は5
時間程度である。処理温度が高い場合は処理時間を短く
する。上記範囲より処理温度が低かったり処理時間が短
いと得られる人参のジンセノサイドRh含量が低い。逆
に処理温度が高すぎたり処理時間が長すぎると熱により
ジンセノサイドや他の有効成分が分解するおそれかあ、
る。組織自体も褐変する。
The treatment time is usually 0.5 to 24 hours, preferably 1 to 1
It is 0 hours. For example, at 110℃, the high temperature treatment time is 5
It takes about an hour. If the processing temperature is high, shorten the processing time. If the treatment temperature is lower or the treatment time is shorter than the above range, the ginsenoside Rh content of the resulting ginseng will be low. On the other hand, if the processing temperature is too high or the processing time is too long, there is a risk that ginsenosides and other active ingredients will decompose due to heat.
Ru. The tissue itself also turns brown.

このように高温処理を行うと1Mi織培養物の細胞組織
が破壊されて細胞液は濃縮される。細胞液には本来、有
機酸が含有されるため、濃縮された細胞液は強い酸性条
件下におかれる。このような酸性条件下では、含有され
るジンセノサイドが加水分解を受けやすくなると考えら
れる。例えば。
When the high temperature treatment is performed in this manner, the cell tissue of the 1Mi textile culture is destroyed and the cell fluid is concentrated. Since cell fluid inherently contains organic acids, concentrated cell fluid is placed under strongly acidic conditions. It is thought that under such acidic conditions, the ginsenosides contained become more susceptible to hydrolysis. for example.

ジンセノサイドReおよびRgはプロトパナキシトリオ
ールにグルコースなどの車ネノ3が結合した形態の化合
物であり、これが加水分解されると糖部分が脱離してジ
ンセノサイドRhが生成する。特にジンセノサイドR[
は薬用人参中の含Th−ffiが比較的高いため、高温
処理を行うことによりジンセノサイドRhが多量に含ま
れる人参が得られる。高温処理は好ましくは密封容器内
で行われる。密封容器内で処理されると1組織培養物は
多湿下で高温処理されることとなり、このような条件下
では、ジンセノサイドの加水分解反応が促進される。得
られた人参は天然の薬用人参の約5倍の割合でジンセノ
サイドRhを含有する。
Ginsenosides Re and Rg are compounds in the form of protopanaxytriol bound to a molecule such as glucose, and when this is hydrolyzed, the sugar moiety is eliminated and ginsenoside Rh is produced. Especially ginsenoside R [
Since the Th-ffi content in medicinal ginseng is relatively high, ginseng containing a large amount of ginsenoside Rh can be obtained by performing high temperature treatment. The high temperature treatment is preferably carried out in a sealed container. When treated in a sealed container, a tissue culture is treated at high temperature under high humidity, and under such conditions, the hydrolysis reaction of ginsenoside is promoted. The obtained ginseng contains ginsenoside Rh at a rate about five times that of natural medicinal ginseng.

高温処理後の人参の含水率は、上記高温処理の条件など
により多少異なるが1通常、50〜80%である。これ
を保存する場合には9次いで、乾燥処理に供する。乾燥
温度は上記高温加熱処理温度よりも低温を採用し1通常
40〜60℃である。通風乾燥(温風乾燥)が好適であ
る。乾燥に要する時間は通常、1時間以上、好ましくは
6〜24時間である。乾燥温度が高すぎるとジンセノサ
イドなどの有効成分が分解し、低すぎると乾燥に長時間
を要するため、カビなどが発生して品質が低下するおそ
れがある。
The moisture content of carrots after high-temperature treatment varies somewhat depending on the conditions of the high-temperature treatment, but is usually 50 to 80%. If this is to be stored, it is then subjected to a drying process. The drying temperature is lower than the above-mentioned high temperature heat treatment temperature, and is usually 40 to 60°C. Ventilation drying (warm air drying) is preferred. The time required for drying is usually 1 hour or more, preferably 6 to 24 hours. If the drying temperature is too high, active ingredients such as ginsenosides will decompose, and if the drying temperature is too low, it will take a long time to dry, which may lead to the growth of mold and deteriorate quality.

(実施例) 以下に本発明を実施例について説明する。(Example) The present invention will be described below with reference to Examples.

天川1に二1 (A)薬用人参の培養:薬用人参(オタネ人参)の組織
の一部を切り取り、これを2・4−ジクロロフェノキシ
酢酸(2・4−D)およびカイネチンをそれぞれ0.5
ppmずつ含有するMS培地で1〜2ケ月組織培養した
。得られたカルスをインドール酢酸(IAA)2ppm
およびカイネチン0.lppmを含有する修正MS培地
を用いて1ケ月間培養した。含水率94%の組織培養物
約500gが得られた。
Tenkawa 1 to 21 (A) Cultivation of medicinal ginseng: A part of the tissue of medicinal ginseng (Panese ginseng) was cut out and treated with 0.5 each of 2,4-dichlorophenoxyacetic acid (2,4-D) and kinetin.
Tissue culture was carried out for 1 to 2 months in MS medium containing ppm. The obtained callus was treated with 2 ppm of indole acetic acid (IAA).
and kinetin 0. The cells were cultured for one month using a modified MS medium containing lppm. Approximately 500 g of tissue culture with a moisture content of 94% was obtained.

(B)人参の高温処理: (^)項で得られた組織培養
物を容量3000calの密封容器に入れ、150℃で
5時間高温処理を行った。
(B) High-temperature treatment of carrots: The tissue culture obtained in section (^) was placed in a sealed container with a capacity of 3000 cal and subjected to high-temperature treatment at 150° C. for 5 hours.

(C)サポニンの抽出=(B)項で得られた高温処理後
の人参5gに50%エタノール200m/を抽出溶媒と
して加え、 50℃で24時間浸漬して抽出を行った。
(C) Extraction of saponin = 200ml of 50% ethanol was added as an extraction solvent to 5g of the high-temperature-treated carrots obtained in section (B), and the mixture was immersed at 50°C for 24 hours to perform extraction.

抽出溶媒を留去して得たエキスを100m1の蒸留水に
溶かし、50mj2のジエチルエーテルを加えて分液ロ
ートで振盪・分離して水層を得、ジエチルエーテル可溶
部を除去した。別にn−ブタノールと1%NaC1水溶
液(蒸留水使用)とを7:3の割合で混合し、水飽和ブ
タノールを調製した。
The extract obtained by distilling off the extraction solvent was dissolved in 100 ml of distilled water, 50 mj2 of diethyl ether was added, and the mixture was shaken and separated using a separatory funnel to obtain an aqueous layer, and the diethyl ether soluble portion was removed. Separately, n-butanol and 1% NaCl aqueous solution (using distilled water) were mixed at a ratio of 7:3 to prepare water-saturated butanol.

この水飽和ブタノール100m/を上記水層に加えて振
盪・分離し、サポニンをブタノール層に抽出した。水層
にはさらに水飽和ブタノール50m7!を加えて振盪・
分離して水層を廃棄し、ブタノール層を得た。このブタ
ノール層と上記ブタノール層とを合わせた後、ブタノー
ル飽和水100+ylNを用いて洗浄を行った。ここで
用いたブタノール飽和水は1%NaC]水溶液(蒸留水
使用)とn−ブタノールとを7:3の割合で混合して調
製した。洗浄後のブタノール層にさらにブタノール飽和
水50m1を加えて洗浄を行った。洗浄により得られた
水層を合わせた後、水飽和ブタノール50mffを加え
て水層からサポニンを回収した。得られたブタノール層
と上記洗浄後のブタノール層とを合わせてエバポレータ
ーで?農務し、粗サポニンを得た。
100 m/ml of this water-saturated butanol was added to the aqueous layer, shaken and separated, and saponin was extracted into the butanol layer. In the water layer, there is also 50m7 of water-saturated butanol! Add and shake.
Separate and discard the aqueous layer to obtain a butanol layer. After combining this butanol layer and the above-mentioned butanol layer, washing was performed using 100+ylN of butanol saturated water. The butanol saturated water used here was prepared by mixing a 1% NaC] aqueous solution (using distilled water) and n-butanol at a ratio of 7:3. After washing, 50 ml of butanol saturated water was further added to the butanol layer for washing. After combining the aqueous layers obtained by washing, 50 mff of water-saturated butanol was added to recover saponin from the aqueous layer. Combine the obtained butanol layer and the above washed butanol layer in an evaporator? He worked on agriculture and obtained crude saponin.

(D) ジンセノサイドの検出:(C)項で得られた粗
サポニンを10m1のメタノールに溶解した。これを薄
層プレートの長手方向端部から’l cmの位置に5μ
2スポツトし、水−酢酸エチル−n−ブタノール(5:
 1 : 4)混液の上層を展開溶媒として19.5c
m展開した。展開後の薄層プレートを24時間自然乾燥
した後、10%硫酸水溶液を均一に噴霧した。このプレ
ートを120℃の乾燥機で7分間加熱した後、高速薄層
クロマトスキャナーC5−920(島津社製)を用い、
  530nmで測定を行った。得られたチャートを第
1図に示す。第1図で1は本実施例で得られた粗サポニ
ンを、2はジンセノサイドRh、およびRg+を含有す
る標準サンプルを示す。
(D) Detection of ginsenosides: The crude saponin obtained in section (C) was dissolved in 10 ml of methanol. Place this at a distance of 5 μm from the longitudinal end of the thin layer plate.
2 spots, water-ethyl acetate-n-butanol (5:
1:4) 19.5c as the developing solvent for the upper layer of the mixture
m expanded. After the developed thin layer plate was air-dried for 24 hours, a 10% aqueous sulfuric acid solution was uniformly sprayed thereon. After heating this plate in a dryer at 120°C for 7 minutes, using a high-speed thin layer chromatography scanner C5-920 (manufactured by Shimadzu Corporation),
Measurements were taken at 530 nm. The obtained chart is shown in FIG. In FIG. 1, 1 represents the crude saponin obtained in this example, and 2 represents a standard sample containing ginsenoside Rh and Rg+.

1においてピークO+ a+ b+ C1d+ e+ 
f+ gおよびhはそれぞれジンセノサイドRo、 I
la、 Rh、 Rc。
1 peak O+ a+ b+ C1d+ e+
f+ g and h are ginsenoside Ro, I, respectively
la, Rh, Rc.

Rd、 Re、 RfおよびRgを示す。2においてピ
ークb1およびピークglはそれぞれジンセノサイドR
b、およびジンセノサイドRgl を示す。各ジンセノ
サイドのピーク位置およびジンセノサイドの含有量を表
1に示す。表1および後述の表2〜表4においてピーク
位置は、薄層プレートのプレート端から各ジンセノサイ
ドのスポットまでの距離を示す。
Rd, Re, Rf and Rg are shown. In 2, peak b1 and peak gl are respectively ginsenoside R.
b, and ginsenoside Rgl are shown. Table 1 shows the peak position and ginsenoside content of each ginsenoside. In Table 1 and Tables 2 to 4 described below, the peak position indicates the distance from the plate edge of the thin layer plate to each ginsenoside spot.

粗サポニン)8液はプレート端から201の距離にスポ
ットしたため1表に示された値から20を差し引いた値
が展開距離に相当する。ジンセノサイド含fffiは各
ピークの面積を示す相対値である。
Crude saponin) 8 solution was spotted at a distance of 201 from the edge of the plate, so the value obtained by subtracting 20 from the value shown in Table 1 corresponds to the spread distance. Ginsenoside content fffi is a relative value indicating the area of each peak.

表1 (^)薬用人参の培養:実施例1−1 (A)項と同様
である。
Table 1 (^) Culture of medicinal ginseng: Example 1-1 Same as section (A).

(B)人参の高温処理二本実施例(A)項で得られたM
i織培養物を実施例1−1(It)項と同様に高温処理
した後、約’l amの厚みに積層して50℃にて3.
5%/n+in、の風量で24時間温風乾燥し、36g
の乾燥品を得た。
(B) Two high-temperature treatments of carrots M obtained in Example (A)
The i-woven culture was treated at high temperature in the same manner as in Example 1-1 (It), then laminated to a thickness of about 1 am and heated at 50°C for 3.
Dry with warm air for 24 hours at an air volume of 5%/n+in, 36g
A dried product was obtained.

(C)サポニンの抽出二本実施例(B)項で得られた乾
燥後の人参5gを実施例1−1(C)項に準じて処理し
、粗サポニンを得た。
(C) Extraction of saponin 2. 5 g of dried ginseng obtained in Example (B) was treated according to Example 1-1 (C) to obtain crude saponin.

(D)  ジンセノサイドの検出二本実施例(C)項で
得られた粗サポニン中のジンセノサイドを実施例1−1
(D)項に準じて検出したところ、第1図とほぼ同一の
チャートが得られた。
(D) Detection of ginsenosides 2.Example 1-1
Detection was performed according to section (D), and a chart almost identical to that in FIG. 1 was obtained.

大籐炭主二上 (A)薬用人参の培養:実施例1−1 (A)項と同様
である。
Large rattan charcoal main two (A) Cultivation of medicinal ginseng: Example 1-1 Same as section (A).

(B)人参の高温処理二本実施例(A)項で得られた組
織培養物を容量3000cnlの密封容器に入れ、11
0℃で5時間高温処理を行った。
(B) High-temperature treatment of carrots (2) The tissue culture obtained in Example (A) was placed in a sealed container with a capacity of 3000 cnl.
High temperature treatment was performed at 0°C for 5 hours.

(C)サポニンの抽出二本実施例(Il)項で得られた
高温処理後の人参5gを用い、実施例1−1 (C)項
に準じて処理し、粗サポニンを得た。
(C) Extraction of saponin 2 Using 5 g of the high-temperature-treated ginseng obtained in Example (Il), the treatment was performed according to Example 1-1 (C) to obtain crude saponin.

(D)  ジンセノサイドの検出二本実施例(C)項で
得られた粗サポニン中のジンセノサイドを実施例1−1
(D)項に準じて検出したところ、第2図に示すチャー
トが得られた。各ジンセノサイドのピーク位置およびジ
ンセノサイド含有量を表2に示す。
(D) Detection of ginsenosides 2.Example 1-1
Detection was performed according to section (D), and the chart shown in FIG. 2 was obtained. Table 2 shows the peak position and ginsenoside content of each ginsenoside.

表2 (八)薬用人参の培養:実施例1−1 (A)項と同様
である。
Table 2 (8) Cultivation of medicinal ginseng: Same as Example 1-1 (A).

(13)人参の高温処理二本実施例(八)項で得られた
組織培養物を実施例2−1(B)項と同様に高温処理し
た後、約’l cmの厚みに積層して60゛Cにて3.
5n?/min、の風量で24時間温風乾燥し、35g
の乾燥品を得た。
(13) High-temperature treatment of carrots (2) The tissue culture obtained in Example (8) was treated at high temperature in the same manner as in Example 2-1 (B), and then layered to a thickness of about 1 cm. 3. At 60°C.
5n? /min, hot air drying for 24 hours, 35g
A dried product was obtained.

(C)サポニンの抽出二本実施例(B)項で得られた乾
燥後の人参5gを実施例1−1(C)項に準じて処理し
、粗サポニンを得た。
(C) Extraction of saponin 2. 5 g of dried ginseng obtained in Example (B) was treated according to Example 1-1 (C) to obtain crude saponin.

(D) ジンセノサイドの検出:本実施例(C)項で得
うれた粗サポニン中のジンセノサイドを実施例1−1(
D)項に準じて検出したところ、第″2図とほぼ同一の
チャートが得られた。ジンセノサイドReとR[の合計
、 RgおよびRhの量を、後述の実施例3−2.4お
よび比較例2−2の結果とともに第5図に示す。第5図
においてジンセノサイド含量は高温処理および乾燥後の
人参1gあたりのmg数である。
(D) Detection of ginsenosides: Ginsenosides in the crude saponin obtained in Section (C) of this Example were detected in Example 1-1 (
Detection was performed according to Section D), and a chart almost identical to that shown in Figure 2 was obtained. The results of Example 2-2 are shown in Figure 5. In Figure 5, the ginsenoside content is expressed in mg per gram of ginseng after high temperature treatment and drying.

去1堆しし1上 (A)薬用人参の培養:実施例1−1 (A)項と同様
である。
(A) Culture of medicinal ginseng: Same as Example 1-1 (A).

(B)人参の高温処理:本実施例(A)項で得られた組
織培養物を容量3000 cイの密封容器に入れ、13
0℃で5時間高温処理を行った。
(B) High-temperature treatment of carrots: The tissue culture obtained in section (A) of this example was placed in a sealed container with a capacity of 3000 cm, and heated for 13 minutes.
High temperature treatment was performed at 0°C for 5 hours.

(C)サポニンの抽出:本実施例(B)項で得られた高
温処理後の人参5gを用い、実施例1−1 (C)項に
卓じて処理し、粗サポニンを得た。
(C) Extraction of saponin: Using 5 g of the high-temperature-treated ginseng obtained in Section (B) of this Example, the treatment was performed in accordance with Section (C) of Example 1-1 to obtain crude saponin.

(D)ジンセノサイドの検出:本実施例(C)項で得ら
れた粗サポニン中のジンセノサイドを実施例1−1(D
)項に準じて検出したところ、第3図に示すチャートが
得られた。各ジンセノサイドのピーク位置およびジンセ
ノサイド含有量を表3に示す。
(D) Detection of ginsenosides: Ginsenosides in the crude saponin obtained in Section (C) of this Example were detected in Example 1-1 (D
), the chart shown in FIG. 3 was obtained. Table 3 shows the peak position and ginsenoside content of each ginsenoside.

表3 スl側LL二I (八)薬用人参の培養:実施例1−1 (A)項と同様
である。
Table 3 Sl side LL2I (8) Culture of medicinal ginseng: Example 1-1 Same as section (A).

(B)人参の高温処理:本実施例(八)項で得られた組
織培養物を実施例3−1(B)項と同様に高温処理した
後、約2CI11の厚みに積層して60℃にて3.5r
rr/min、の風量で24時間温風乾燥し、35gの
乾燥品を得た。
(B) High-temperature treatment of carrots: The tissue culture obtained in Section (8) of this Example was treated at high temperature in the same manner as in Example 3-1 (B), and then laminated to a thickness of about 2 CI11 at 60°C. 3.5r at
It was dried with hot air for 24 hours at an air flow rate of rr/min to obtain 35 g of a dried product.

(C)サポニンの抽出二本実施例(B)項で得られた乾
燥後の人参5gを実施例1−1(C)項に阜じて処理し
、粗サポニンを得た。
(C) Extraction of saponin 2. 5 g of dried carrots obtained in Example (B) was treated as in Example 1-1 (C) to obtain crude saponin.

(D) ジンセノサイドの検出二本実施例(C)項で得
られた粗サポニン中のジンセノサイドを実施例1−1(
D)項に準じて検出したところ、第3図とほぼ同一のチ
ャートが得られた。
(D) Detection of ginsenosides Two ginsenosides in the crude saponin obtained in Example (C) were detected in Example 1-1 (
Detection was performed according to section D), and a chart almost identical to that shown in FIG. 3 was obtained.

去籐奥↓ (A)薬用人参の培養:実施例1−1 (A)項と同様
である。
(A) Culture of medicinal ginseng: Example 1-1 Same as section (A).

(B)人参の高温処理二本実施例(八)項で得られた組
織培養物を実施例1−1(B)項と同様に高温処理した
後、約2cfflの厚みに積層して60℃にて3.5m
/min、の風量で24時間温風乾燥し、35gの乾燥
品を得た。
(B) High-temperature treatment of carrots (2) The tissue culture obtained in Example (8) was treated at high temperature in the same manner as in Example 1-1 (B), and then laminated to a thickness of about 2 cffl at 60°C. 3.5m at
The product was dried with hot air for 24 hours at an air flow rate of /min to obtain 35 g of dried product.

(C)サポニンの抽出:本実施例(B)項で得られた乾
燥後の人参5gを実施例1−1(C)項に準じて処理し
、粗サポニンを得た。
(C) Extraction of saponin: 5 g of dried ginseng obtained in section (B) of this example was treated according to section (C) of Example 1-1 to obtain crude saponin.

(D) ジンセノサイドの検出二本実施例(C)項で得
られた粗サポニン中のジンセノサイドを実施例1−1(
D)項に準じて検出したところ、第1図とほぼ同一のチ
ャートが得られた。
(D) Detection of ginsenosides Ginsenosides in the crude saponin obtained in Example (C) were detected in Example 1-1 (
Detection was performed according to section D), and a chart almost identical to that shown in FIG. 1 was obtained.

比較例1 (八)薬用人参の培養:実施例L−1(A)項と同様で
ある。
Comparative Example 1 (8) Cultivation of medicinal ginseng: Same as Example L-1 (A).

(B)サポニンの抽出:本比較例(A)項で得られた組
織培養物を約2 cmの厚みに積層して60℃にて3.
5 m/min、の風量で24時間温風乾燥し38gの
乾燥品を得た。この乾燥品5gを用い、実施例1−1 
 (C)項に準じて処理し、粗サポニンを得た。
(B) Extraction of saponin: The tissue culture obtained in section (A) of this comparative example was layered to a thickness of about 2 cm and heated at 60°C for 3.
Hot air drying was performed for 24 hours at an air flow rate of 5 m/min to obtain 38 g of dried product. Using 5 g of this dried product, Example 1-1
Crude saponin was obtained by processing according to section (C).

(C) ジンセノサイドの検出二本比較例(B)項で得
られた粗サポニン中のジンセノサイドを実施例1−1(
D)項に準じて検出したところ、ジンセノサイドRhは
ほとんど含有されていないことが確認された。
(C) Detection of ginsenosides Two comparative examples Ginsenosides in the crude saponin obtained in section (B) were detected in Example 1-1 (
Detection according to section D) confirmed that almost no ginsenoside Rh was contained.

此MJJLL二上 (八)薬用人参の培養:実施例1−1(A)項と同様で
ある。
(8) Cultivation of medicinal ginseng: Same as in Example 1-1 (A).

(B)人参の高温処理二本実施例(^)項で得られた組
織培養物を容量3000 c−の密封容器に入れ、90
℃で5時間高温処理を行った。
(B) Two high-temperature treatments of carrots The tissue culture obtained in Example (^) was placed in a sealed container with a capacity of 3000 c-, and
High temperature treatment was performed at ℃ for 5 hours.

(C)サポニンの抽出二本実施例(B)項で得られた高
温処理後の人参5gを用い、実施例1−1 (C)項に
準じて処理し、粗サポニンを得た。
(C) Extraction of saponin 2 Using 5 g of the high-temperature-treated ginseng obtained in Example (B), the treatment was performed according to Example 1-1 (C) to obtain crude saponin.

(D) ジンセノサイドの検出:本比較例(C)項で得
られた粗サポニン中のジンセノサイドを実施例1−1(
D)項に準じて検出したところ、第4図に示すチャート
が得られた。第4図において3は本比較例で得られた粗
サポニンを、4はジンセノサイドRhおよびRgを含有
する標準サンプルを示す。
(D) Detection of ginsenosides: Ginsenosides in the crude saponin obtained in section (C) of this comparative example were detected in Example 1-1 (
Detection was performed according to section D), and the chart shown in FIG. 4 was obtained. In FIG. 4, 3 indicates the crude saponin obtained in this comparative example, and 4 indicates a standard sample containing ginsenosides Rh and Rg.

各ジンセノサイドのピーク位置およびジンセノサイド含
有量を表4に示す。
Table 4 shows the peak position and ginsenoside content of each ginsenoside.

表4 (八)薬用人参の培養:実施例1−1 (A)項と同様
である。
Table 4 (8) Cultivation of medicinal ginseng: Same as Example 1-1 (A).

(B)人参の高温処理二本実施例(^)項で得られた組
織培養物を比較例1−1(B)項と同様に高温処理した
後、約2cmの厚みに積層して60℃にて3゜5rrr
/min、の風量で24時間温風乾燥し、37gの乾燥
品を得た。
(B) High-temperature treatment of carrots Two The tissue culture obtained in Example (^) was treated at high temperature in the same manner as in Comparative Example 1-1 (B), then laminated to a thickness of about 2 cm and heated to 60°C. 3゜5rrr at
The product was dried with hot air for 24 hours at an air flow rate of /min to obtain 37 g of a dried product.

(C)サポニンの抽出:本比較例(B)項で得られた乾
燥後の人参5gを実施例1−1(C)項に準じて処理し
、粗サポニンを得た。
(C) Extraction of saponin: 5 g of dried ginseng obtained in section (B) of this comparative example was treated according to section (C) of Example 1-1 to obtain crude saponin.

(D)ジンセノサイドの検出二本比較例(C)項で得ら
れた粗サポニン中のジンセノサイドを実施例1−1(D
)項に準じて検出したところ、第4図とほぼ同一のチャ
ートが得られた。
(D) Detection of ginsenosides Two comparative examples Ginsenosides in the crude saponin obtained in section (C) were detected in Example 1-1 (D
), a chart almost identical to that in FIG. 4 was obtained.

表1〜表4および第1図〜第5図により、高温処理が行
われるとジンセノサイドRhを多量に含有する人参が得
られることが明らかである。
From Tables 1 to 4 and Figures 1 to 5, it is clear that ginseng containing a large amount of ginsenoside Rh can be obtained by high temperature treatment.

(発明の効果) 本発明によれば、このように、薬用人参細胞培養物を高
温処理することによりジンセノサイドRhを多量に含有
する人参が得られる。この人参は特定の条件下で乾燥す
ることにより1品質を変化させることなく乾燥人参とし
、長期間保存することが可能である。使用する薬用人参
細胞培養物は通常の組織培養法により短時間で大量に得
られるため、ジンセノサイドRhを多量に含有する人参
が安価に得られうる。このような人参を用いて、ジンセ
ノサイドRhについての研究がさらに進められうると期
待される。
(Effects of the Invention) According to the present invention, ginseng containing a large amount of ginsenoside Rh can be obtained by treating a medicinal ginseng cell culture at high temperature. By drying this carrot under specific conditions, it can be made into dried carrot without any change in quality and can be stored for a long period of time. Since the medicinal ginseng cell culture used can be obtained in large quantities in a short period of time by conventional tissue culture methods, ginseng containing a large amount of ginsenoside Rh can be obtained at low cost. It is expected that research on ginsenoside Rh can be further advanced using such ginseng.

4、メ の′τ゛′なL 第1図〜第3図は本発明方法により得られる薬用人参か
ら抽出したサポニン中の各ジンセノサイドを示す薄層ク
ロマトスキャナーによるチャート;第4図は本発明方法
よりも低温で処理した薬用人参から抽出したサポニン中
の各ジンセノサイドを示ず薄層クロマトスキャナーによ
るチャート;そして第5図は高温処理温度を変えたとき
に、得られる人参中の各ジンセノサイド含量を比較した
グラフである。
4. Figures 1 to 3 are thin-layer chromatograph charts showing each ginsenoside in saponin extracted from medicinal ginseng obtained by the method of the present invention; Figure 4 is a chart obtained by the method of the present invention A chart taken using a thin layer chromatography scanner showing the ginsenosides in saponin extracted from medicinal ginseng treated at a lower temperature; and Figure 5 compares the content of each ginsenoside in the ginseng obtained when the high temperature treatment temperature is changed. This is a graph.

以上that's all

Claims (1)

【特許請求の範囲】 1、薬用人参から得られる組織培養物を高温処理しジン
セノサイドRhの含有量を高める工程を包含する薬用人
参の処理方法。 2、前記高温処理が密封容器内で行われる特許請求の範
囲第1項に記載の処理方法。 3、前記高温処理が110〜160℃で0.5〜24時
間行われる特許請求の範囲第1項に記載の処理方法。 4、薬用人参から得られる組織培養物を高温処理しジン
セノサイドRhの含有量を高め、次いで、該高温処理温
度よりも低温で乾燥処理する工程を包含する薬用人参の
処理方法。 5、前記高温処理が密封容器内で行われる特許請求の範
囲第4項に記載の処理方法。 6、前記高温処理が110〜160℃で0.5〜24時
間行われる特許請求の範囲第4項に記載の処理方法。 7、前記乾燥処理が40〜60℃の温風乾燥である特許
請求の範囲第4項に記載の処理方法。
[Scope of Claims] 1. A method for treating medicinal ginseng, which includes the step of treating a tissue culture obtained from medicinal ginseng at high temperature to increase the content of ginsenoside Rh. 2. The treatment method according to claim 1, wherein the high temperature treatment is performed in a sealed container. 3. The treatment method according to claim 1, wherein the high temperature treatment is performed at 110 to 160°C for 0.5 to 24 hours. 4. A method for treating medicinal ginseng, which includes the steps of treating a tissue culture obtained from medicinal ginseng at a high temperature to increase the content of ginsenoside Rh, and then drying it at a lower temperature than the high temperature treatment temperature. 5. The treatment method according to claim 4, wherein the high temperature treatment is performed in a sealed container. 6. The treatment method according to claim 4, wherein the high temperature treatment is performed at 110 to 160°C for 0.5 to 24 hours. 7. The processing method according to claim 4, wherein the drying process is hot air drying at 40 to 60°C.
JP169586A 1986-01-08 1986-01-08 Treatment of panax ginseng Pending JPS62158490A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP169586A JPS62158490A (en) 1986-01-08 1986-01-08 Treatment of panax ginseng

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP169586A JPS62158490A (en) 1986-01-08 1986-01-08 Treatment of panax ginseng

Publications (1)

Publication Number Publication Date
JPS62158490A true JPS62158490A (en) 1987-07-14

Family

ID=11508666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP169586A Pending JPS62158490A (en) 1986-01-08 1986-01-08 Treatment of panax ginseng

Country Status (1)

Country Link
JP (1) JPS62158490A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01217205A (en) * 1988-02-25 1989-08-30 Ishikawajima Harima Heavy Ind Co Ltd Band plate shape detector
US5776460A (en) * 1995-06-07 1998-07-07 Man Ki Park Processed ginseng product with enhanced pharmacological effects
KR100444368B1 (en) * 2001-06-13 2004-08-16 주식회사 한국인삼공사 The manufacturing process for the specific ginsenoside from panax ginseng hairy roots by heat treatment
JP2008501791A (en) * 2004-06-11 2008-01-24 ユニジェン インク. Composition for preventing or treating vascular stenosis and restenosis comprising ginsenoside
US7985848B2 (en) 2005-03-18 2011-07-26 Unigen, Inc. Pharmaceutical composition for preventing and treating diabetes or glucose control abnormality comprising ginsenosides
WO2014042359A1 (en) * 2012-09-12 2014-03-20 Kim Su-Gyum Method for producing roasted red ginseng and roasted red ginseng produced by same
JP2017529835A (en) * 2014-08-22 2017-10-12 ウェルキー ホールディングス リミテッドWellkey Holdings Limited Ginseng extract containing ginseng or ginseng containing a rare ginsenoside, or a method for producing ginseng-forming plant stem cells or extracts thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01217205A (en) * 1988-02-25 1989-08-30 Ishikawajima Harima Heavy Ind Co Ltd Band plate shape detector
US5776460A (en) * 1995-06-07 1998-07-07 Man Ki Park Processed ginseng product with enhanced pharmacological effects
KR100444368B1 (en) * 2001-06-13 2004-08-16 주식회사 한국인삼공사 The manufacturing process for the specific ginsenoside from panax ginseng hairy roots by heat treatment
JP2008501791A (en) * 2004-06-11 2008-01-24 ユニジェン インク. Composition for preventing or treating vascular stenosis and restenosis comprising ginsenoside
US7985848B2 (en) 2005-03-18 2011-07-26 Unigen, Inc. Pharmaceutical composition for preventing and treating diabetes or glucose control abnormality comprising ginsenosides
WO2014042359A1 (en) * 2012-09-12 2014-03-20 Kim Su-Gyum Method for producing roasted red ginseng and roasted red ginseng produced by same
JP2017529835A (en) * 2014-08-22 2017-10-12 ウェルキー ホールディングス リミテッドWellkey Holdings Limited Ginseng extract containing ginseng or ginseng containing a rare ginsenoside, or a method for producing ginseng-forming plant stem cells or extracts thereof
US10646528B2 (en) 2014-08-22 2020-05-12 Wellkey Holdings Limited Method for preparing extract of genus Panax including wild ginseng or ginseng, or cambial meristematic cells derived from genus panax or extract thereof containing rare ginsenosides in high quantity

Similar Documents

Publication Publication Date Title
CN104127468A (en) Preparation extraction process of Maca extract
WO2017005134A1 (en) Preparation method and use of linseed polysaccharide having antiviral and immunological activity
CN111035666A (en) Ginseng extract with high content of rare saponin, ginseng wine and ginseng oral liquid
JPS62158490A (en) Treatment of panax ginseng
CN107412440A (en) A kind of compound oral liquid for tonifying blood containing red skin of peanut and its quality determining method
KR20100043725A (en) Changes of protopanaxadiol ginsenosides in ginseng leaves by steaming heat treatment
CN107216405A (en) The preparation technology and its structure sequence of a kind of highland barley beta glucan
UA83683C2 (en) Method for the production of a storage-resistant ivy leaf extract, extract, use thereof and medicinal agent
CN101181328A (en) Method for producing ginseng fruit and ginseng flower stalk with high content of ginsenoside
CN107793492A (en) A kind of extracting method of fructus cannabis polysaccharide
CN114159484B (en) Preparation process and application of American ginseng and black ginseng
CN108324798A (en) A kind of converted products and purposes of S. photeinocarpum
KR20100043723A (en) Changes of protopanaxadiol ginsenosides in ginseng leaves by far infrared heat treatment
CN108969580B (en) Preparation method and application of blue cloth total tannin
RU2104025C1 (en) Method of ginseng dry extract preparing
MacDougall et al. Effect of initial drying temperature on the apparent lignin content of plant tissues
CN113440445A (en) Preparation method of ginseng cell water and application of obtained ginseng cell water
CN115521387B (en) Acidic polysaccharide and method for separating acidic polysaccharide from basil seed gum
JPH0327537B2 (en)
JPS6239529A (en) Production of medicinal ginseng extract
CN107793493A (en) A kind of extracting method of grub polysaccharide and its application
JPS6371160A (en) Extract powder of ginseng and production thereof
KR20120035472A (en) The manufacturing method of compound k
KR20080088829A (en) Method for preparing red ginseng from tissue cultured mountain ginseng using extruding process
JPH03227935A (en) Production of powdery extract of medical ginseng